Intra-Cellular Therapies (ITCI) - Margin reged

Intra-Cellular Therapies (ITCI) is reducing its reliance on a single drug by expanding the application of Caplyta for the treatment of CNS disorders. The gross margin percentage provided by the GURU.Markets system confirms this trend, and 91.60 shows the level of this metric. The company's revenues are based on the sale of treatments for bipolar depression, while drug production is fully outsourced to third-party contractors, maintaining control over patents.
Rincian metrik komprehensif lan analitis Intra-Cellular (ITCI)

Intra-Cellular Therapies (ITCI) specializes in developing the innovative drug Caplyta for the treatment of psychiatric disorders. The gross margin here quantifies production efficiency by subtracting direct costs from total revenue to assess operational profitability. Growth in this metric confirms the business's ability to scale sales without a proportional increase in expenses, which is clearly reflected in the gross margin dynamics as the company moves toward profitability.